Ablynx N.v.

Vib Vzw

Vrije Universiteit Brussel

Peter Vanlandschoot

Catelijne Stortelers

Johannes Joseph Wilhelmus De Haard

Michael John Scott Saunders

Regorius Leurs

Martine Smit

Erik Depla

Maria Gonzalez Pajuelo

Philippe Van Rompaey

Dominique Schols

Christophe Blanchetot

Francis Descamps

Pascal Gerard Merchiers

Jose Melero

Sven Jähnichen

Xavier Saelens

Bert Schepens

David Andre Baptiste Maussang-Detaille

Karen Silence

Hans De Haard

Peter Verheesen

Erwin Sablon

Renee De Bruin

Edward Dolk

Marie-Paule Lucienne Armanda Bouche

Maarten Van Roy

Stefan De Buck

Mark Vaeck

Paul M P Van Bergen En Henegouwen

Hugo Soares

Michael John Saunders

Stephanie Staelens

Patrick De Baetselier

Alexander Szyroki

Anna Hultberg

Jo Van Ginderachter

Annelies Roobrouck

Ines Cabrito

Johannes Joseph De Haard

David Andre Baptiste Maussang Detaille

Maria Joao Saraiva

Michael Marie Harmsen

Nigel J Temperton

Robert Anthony Weiss

Cornelis Theodorus Verrips

Bram Maassen

Hendrik Adams

Amanda Sparkes

Maria Gonzalez

Benoît Stijlemans

Steven Van Gucht

David André Baptiste Maussang-Detaille

Nigel James Temperton

Renée De Bruin

Sven Jaehnichen

Miguel Conde

Marie-Paule Lucienne Bouche

The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

The present invention relates to immunoglobulin single variable domains that bind MIF and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.

Immunoglobulin single variable domains directed against macrophage migration inhibitory factor

The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.

Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity

The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumor growth.

Biological materials related to CXCR7

The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.

Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis

The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Amino acid sequences of the present invention may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.

Amino acid sequences directed against cellular receptors for viruses and bacteria

The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.

In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.

Pulmonary administration of immunoglobulin single variable domains and constructs thereof

The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders

Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis

The present invention relates to amino acid sequences that are directed against (as defined herein) G-protein coupled receptors (GPCRs) and in particular to CXCR4 and CXCR7, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 'amino acid sequences of the invention', 'compounds of the invention', and &#x201c;polypeptides of the invention&#x201d;, respectively). Furthermore, the invention provides a new method of making amino acid sequences that are directed against transmembrane protein, and in particular for multiple spanning transmembrane proteins for which the native conformation cannot be reproduced in other &#x201c;in vitro&#x201d; system (e.g. GPCRs in general).

Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same

Growing community of inventors

Bellem, Belgium

Peter Vanlandschoot